Protara Therapeutics (TARA) Total Current Liabilities (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Total Current Liabilities of $8.9 million for Q1 2026, up 27.13% year-over-year from $7.0 million in Q1 2025, and down 18.44% quarter-over-quarter from $10.9 million in Q4 2025.
Protara Therapeutics (TARA) Total Current Liabilities (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Total Current Liabilities for 14 consecutive years, with $8.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 27.13% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at $8.9 million (up 27.13% YoY), while the FY2025 annual figure was $10.9 million, changed 0.2% from the prior year.
- Total Current Liabilities declined to $8.9 million in Q1 2026 per TARA's latest filing, from $10.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $11.0 million in Q4 2024 and bottomed at $2.9 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $6.9 million across 5 years, with a median of $6.4 million in 2023.
- Annual changes were most pronounced in 2023 — Total Current Liabilities surged 124.05% — and 2024, when it slipped 14.18%.
- Protara Therapeutics' Total Current Liabilities stood at $5.7 million in 2022, then grew by 7.13% to $6.1 million in 2023, then jumped by 78.26% to $11.0 million in 2024, then retreated by 0.2% to $10.9 million in 2025, then decreased by 18.44% to $8.9 million in 2026.
- Business Quant data shows TARA's Total Current Liabilities at $8.9 million in Q1 2026, $10.9 million in Q4 2025, and $9.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 13.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.32 Mn |
| Mar 31, 2026 | 8.92 Mn |
| Dec 31, 2025 | 10.94 Mn |
| Sep 30, 2025 | 9.91 Mn |
| Jun 30, 2025 | 9.76 Mn |
| Mar 31, 2025 | 7.02 Mn |
| Dec 31, 2024 | 10.96 Mn |
| Sep 30, 2024 | 8.64 Mn |
| Jun 30, 2024 | 5.65 Mn |
| Mar 31, 2024 | 5.50 Mn |
| Dec 31, 2023 | 6.15 Mn |
| Sep 30, 2023 | 6.78 Mn |
| Jun 30, 2023 | 4.93 Mn |
| Mar 31, 2023 | 6.41 Mn |
| Dec 31, 2022 | 5.74 Mn |
| Sep 30, 2022 | 3.71 Mn |
| Jun 30, 2022 | 3.49 Mn |
| Mar 31, 2022 | 2.86 Mn |
| Dec 31, 2021 | 4.30 Mn |
| Sep 30, 2021 | 3.69 Mn |